De Caterina Raffaele, Di Gioacchino Lorena
G. d'Annunzio University, Chieti, Italy.
Rev Port Cardiol. 2003 Jul-Aug;22(7-8):995-1002.
Antagonists of platelet glycoprotein IIb/IIIa have an approved role in preventing acute complications and coronary events in the setting of percutaneous coronary interventions (PCI). Their use in unstable coronary syndromes out of the PCI setting is however debated. This paper summarizes reasons for the ongoing debate and highlights areas of uncertainty.
血小板糖蛋白IIb/IIIa拮抗剂在预防经皮冠状动脉介入治疗（PCI）时的急性并发症和冠状动脉事件方面具有已获批准的作用。然而，它们在PCI以外的不稳定冠状动脉综合征中的应用仍存在争议。本文总结了持续争议的原因，并突出了不确定的领域。
